End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.68 CNY | -3.14% | -2.06% | -29.65% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 3.91 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.65% | 1.64B | B | ||
+44.48% | 54.04B | B- | ||
+43.57% | 41.96B | A | ||
-0.86% | 41.92B | B | ||
-7.59% | 28.35B | C | ||
+12.30% | 26.35B | B- | ||
-21.83% | 19B | B | ||
+7.15% | 13B | B+ | ||
+29.40% | 12.28B | C+ | ||
+25.15% | 12.19B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603127 Stock
- Ratings Joinn Laboratories(China)Co.,Ltd.